What is Sensorion?
Founded in 2009 and headquartered in Montpellier, France, Sensorion is dedicated to the restoration, treatment, and prevention of hearing loss. The company operates within the specialized field of audiology and otology, leveraging its clinical-stage development pipeline to address unmet medical needs. Its focus on innovative therapies positions it as a key player in the biotech sector's pursuit of solutions for auditory impairments.
How much funding has Sensorion raised?
Sensorion has raised a total of $64.8M across 2 funding rounds:
Grant
$10.4M
Other Financing Round
$54.4M
Grant (2019): $10.4M with participation from Hospital Research-University
Other Financing Round (2024): $54.4M led by Invus, Sofinnova Partners, and Redmile Group
Key Investors in Sensorion
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services. The company was founded in 1985 and is headquartered in New York City, New York.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the U.S. and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs.
Redmile Group
Redmile Group LLC is a company that operates in the Venture Capital & Private Equity industry. It employs 20to49 people and has 5Mto10M of revenue. The company is headquartered in New York City, New York.
What's next for Sensorion?
The recent major strategic investment signals a pivotal phase for Sensorion, likely enabling the acceleration of its clinical trials and the advancement of its therapeutic candidates through regulatory pathways. This backing is expected to fuel further research and development, potentially expanding its portfolio and solidifying its market presence in the competitive landscape of hearing loss treatments. The company's trajectory suggests a strong emphasis on translating scientific breakthroughs into tangible patient benefits.
See full Sensorion company page
